Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.50 |
| ▸ | MTOR | P42345 | 9/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442229 | 0.85 | PIK3CA (0.53) | PIK3CAMTORPIK3CGPIK3CDKDM4E | |
| SCHEMBL4443377 | 0.84 | PIK3CA (0.70) | PIK3CAMTORPIK3CGRAF1BRAF | |
| SCHEMBL4440268 | 0.84 | PIK3CA (0.62) | PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4449352 | 0.83 | KDM4E (0.54) | GAANPSR1PIK3CAMTORPIK3CG | |
| SCHEMBL4442920 | 0.81 | PIK3CA (0.50) | PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4443717 | 0.81 | PIK3CA (0.58) | PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4442257 | 0.81 | PIK3CA (0.71) | PIK3CAMTORPIK3CGPIK3CDKDM4E | |
| SCHEMBL4437743 | 0.80 | PIK3CA (0.72) | PIK3CAMTORPIK3CGRAF1BRAF | |
| SCHEMBL4448951 | 0.80 | MEN1 (0.63) | PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4998903 | 0.78 | PIK3CA (0.67) | PIK3CAMTORPIK3CGPIK3CDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125815-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008116129-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, MTMR1 | GAA 510/4885NPSR1 4258/4885AR 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.